Abstract
The human transporters organic anion transporter 1 (OAT1), organic anion transporter 3 (OAT3) and organic cation transporter 2 (OCT2) are membrane proteins involved in the renal clearance of substances from the body. While the original purpose of these clearance pathways was likely the removal of naturally occurring metabolism byproducts, they are also responsible for secretion of many drugs. Various assay systems have been developed to study the interactions of drugs with these transporters as either substrates or inhibitors, since a reduction in drug clearance (due to inhibition of transport of one drug by a co-administered drug) could result in elevated exposure and toxicity. This chapter will provide a brief background on the transporters and how they function, highlight the importance of using in vitro test systems to evaluate the potential for drug-drug interactions (DDIs), and provide a detailed procedure for an assay using transfected human embryonic kidney (HEK293) cells.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Giacomini KM, Huang SM, Tweedie DJ et al (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9(3):215–236
Giacomini KM, Sugiyama Y (2005) Membrane transporters and drug response. In: Brunton L et al (eds) Goodman and Gilman’s The pharmacological basis of therapeutics. McGraw‐Hill, New York, pp 41–70
Lepist EI, Ray AS (2012) Renal drug-drug interactions: what we have learned and where we are going. Expert Opin Drug Metab Toxicol 8(4):433–448
Mizuno N et al (2003) Impact of drug transporter studies on drug discovery and development. Pharmacol Rev 55(3):425–461
US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) (2012) Guidance for industry. Drug interaction studies—study design, data analysis, implications for dosing, and labeling recommendations. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf
European Medicines Agency, Committee for Human Medicinal Products (CHMP) (2012) Guideline on the investigation of drug interactions. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129606.pdf
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this protocol
Cite this protocol
Wang, Y., Behler, N. (2014). In Vitro Characterization of Renal Transporters OAT1, OAT3, and OCT2. In: Caldwell, G., Yan, Z. (eds) Optimization in Drug Discovery. Methods in Pharmacology and Toxicology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-742-6_24
Download citation
DOI: https://doi.org/10.1007/978-1-62703-742-6_24
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-741-9
Online ISBN: 978-1-62703-742-6
eBook Packages: Springer Protocols